Division of Women's Health Internal Medicine, Mayo Clinic, 13400 E. Shea Blvd, Scottsdale, AZ 85259, USA.
Mayo Clin Proc. 2011 Jul;86(7):673-80, quiz 680. doi: 10.4065/mcp.2010.0714. Epub 2011 Apr 29.
The change in hormonal milieu associated with perimenopause and menopause can lead to a variety of symptoms that can affect a woman's quality of life. Postmenopausal hormone therapy (HT) is an effective, well-tolerated treatment for these symptoms. However, combined HT consisting of conjugated equine estrogen and medroxyprogesterone acetate has been associated with an increased number of health risks when compared with conjugated equine estrogen alone or placebo. As a result, some women are turning to alternative hormonal formulations known as compounded bioidentical HT because they perceive them to be a safer alternative. This article defines compounded bioidentical HT and explores the similarities and differences between it and US Food and Drug Administration-approved HT. We will examine the major claims made by proponents of compounded bioidentical HT and recommend strategies for management of patients who request bioidentical HT from physicians.
围绝经期和绝经后与激素环境变化相关的各种症状会影响女性的生活质量。绝经后激素治疗（HT）是治疗这些症状的有效且耐受良好的方法。然而，与单独使用结合马雌激素或安慰剂相比，联合使用结合马雌激素和醋酸甲羟孕酮的联合 HT 会增加更多的健康风险。因此，一些女性转向使用称为复合生物等同 HT 的替代激素制剂，因为她们认为这是一种更安全的选择。本文定义了复合生物等同 HT，并探讨了它与美国食品和药物管理局批准的 HT 之间的异同。我们将检查复合生物等同 HT 的支持者提出的主要主张，并为要求医生开具生物等同 HT 的患者推荐管理策略。
